MELISSA MEDINA: Open Payments
NPI 1639587439 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$387 in 16 payments from 9 companies in 2025. Trend: 2023 $2,146 · 2024 $6,172 · 2025 $387
Food & beverage: $387
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 3 | $130 |
| Celltrion USA Inc. | 3 | $64 |
| ABBVIE INC. | 3 | $56 |
| Gilead Sciences, Inc. | 2 | $45 |
| Janssen Biotech, Inc. | 1 | $20 |
| Braintree Laboratories, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
Products named: IBSRELA, VEGZELMA, MAVYRET, TREMFYA, SUTAB, OMVOH, ENTYVIO, VOQUEZNA.
Industry payments across TX — which companies pay providers there.
